Terms: = Thyroid cancer AND ER, estrogen receptor AND Prognosis
158 results:
1. Isocitrate dehydrogenase 2 regulates the proliferation of triple-negative breast cancer through the ferroptosis pathway.
Zhang C; Zhou Y; Chen T; Bhushan S; Sun S; Zhang P; Yang Y
Sci Rep; 2024 Feb; 14(1):4732. PubMed ID: 38413708
[TBL] [Abstract] [Full Text] [Related]
2. Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in HER2-positive breast cancer.
Sha R; Dong X; Yan S; Dai H; Sun A; You L; Guo Z
Sci Rep; 2024 Feb; 14(1):2908. PubMed ID: 38316885
[TBL] [Abstract] [Full Text] [Related]
3. USP46 enhances tamoxifen resistance in breast cancer cells by stabilizing PTBP1 to facilitate glycolysis.
Gao S; Wang Y; Xu Y; Liu L; Liu S
Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):167011. PubMed ID: 38176460
[TBL] [Abstract] [Full Text] [Related]
4. ER+/PR- phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancer.
Luo Y; Li Q; Fang J; Pan C; Zhang L; Xu X; Qian S; Zhao X; Hou L
Sci Rep; 2024 Jan; 14(1):197. PubMed ID: 38167641
[TBL] [Abstract] [Full Text] [Related]
5. Clinical characteristics and prognosis of primary small cell carcinoma of the breast: a propensity score-matched, population-based study.
Yin L; Yin AH; Pu CC
BMJ Open; 2023 Dec; 13(12):e073841. PubMed ID: 38097248
[TBL] [Abstract] [Full Text] [Related]
6. TNFRSF19 promotes endoplasmic reticulum stress-induced paraptosis via the activation of the MAPK pathway in triple-negative breast cancer cells.
Liu S; Tian Y; Liu C; Gui Z; Yu T; Zhang L
Cancer Gene Ther; 2024 Feb; 31(2):217-227. PubMed ID: 37990061
[TBL] [Abstract] [Full Text] [Related]
7. Identification of UBFD1 as a prognostic biomarker and molecular target among estrogen receptor-positive breast cancer.
Duan L; Liu R; Cui X; Zhang Q; Cao D; Chen M; Zhang A
Biochem Biophys Res Commun; 2023 Dec; 686():149171. PubMed ID: 37922573
[TBL] [Abstract] [Full Text] [Related]
8. The Association of Melanoma-Associated Antigen-C Gene With Clinicopathological Characteristics and prognosis in Breast cancer: A Systematic Review and Meta-Analysis.
Lin X; Huo J; Su H; Xu Y; Zhang F
Clin Breast Cancer; 2024 Jan; 24(1):7-16. PubMed ID: 37872029
[TBL] [Abstract] [Full Text] [Related]
9. BRAF
Cao J; Chen B; Zhu X; Sun Y; Li X; Zhang W; Wang X
Endocrine; 2024 Apr; 84(1):160-170. PubMed ID: 37851243
[TBL] [Abstract] [Full Text] [Related]
10. Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study.
Han N; Lu C; Li J; Wang C; Zhao Z; Zhang Y; Liu X; Si Z; Wang G; Wang Z; Li F; Wang X
Front Endocrinol (Lausanne); 2023; 14():1222470. PubMed ID: 37810895
[TBL] [Abstract] [Full Text] [Related]
11. Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer.
Jiang C; Zhu Y; Chen H; Lin J; Xie R; Li W; Xue J; Chen L; Chen X; Xu S
Cell Death Dis; 2023 Oct; 14(10):653. PubMed ID: 37803002
[TBL] [Abstract] [Full Text] [Related]
12. Long-term prognostic analysis of children and adolescents with differentiated thyroid carcinoma based on therapeutic response to initial radioiodine therapy.
Wang C; Lu G; Li Y; Liu X; Wang G; Lu C; Li J; Luo Q; Zhang Q; Sun M; Wang X; Wang R
Front Endocrinol (Lausanne); 2023; 14():1217092. PubMed ID: 37600705
[TBL] [Abstract] [Full Text] [Related]
13. Clinical characteristics and prognosis of postpartum breast cancer.
Paik PS; Choi JE; Lee SW; Lee YJ; Kang YJ; Lee HJ; Bae SY;
Breast Cancer Res Treat; 2023 Nov; 202(2):275-286. PubMed ID: 37542632
[TBL] [Abstract] [Full Text] [Related]
14. Primary Ovarian Small Cell Carcinoma of Pulmonary Type: Analysis of 6 Cases and Review of 31 Cases in the Literatures.
Chen X; Liu HL; Wang JS; Zhao FH
Chin Med Sci J; 2023 Jun; 38(2):130-137. PubMed ID: 37286512
[TBL] [Abstract] [Full Text] [Related]
15. Correlation of PKM2 Expression With HER2/neu and Additional Breast cancer Biomarkers and its Prognostic Significance.
Al-Qudah MA; Al-Keilani MS; Obeidat M; Haddad HK; Bdeir R; Samman LM
Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):363-370. PubMed ID: 37212690
[TBL] [Abstract] [Full Text] [Related]
16. Study on Clinicopathological Features and Risk Factors of Patients with Multiple Primary Breast cancers and thyroid Disease.
Li J; Liu Y; Jin J; Shi Q; Ji Y; Zhang B; Hu P
Mediators Inflamm; 2023; 2023():3133554. PubMed ID: 37152372
[TBL] [Abstract] [Full Text] [Related]
17. Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast cancer With 2 Activating HER2 Mutations.
Tian H; Qu M; Zhang G; Yuan L; Shi Q; Wang Y; Yang Y; Zhang Y; Qi X
Oncologist; 2023 Jul; 28(7):e534-e541. PubMed ID: 37120151
[TBL] [Abstract] [Full Text] [Related]
18. The impact of PIK3CA mutations and PTEN expression on the effect of neoadjuvant therapy for postmenopausal luminal breast cancer patients.
Hayama S; Nakamura R; Ishige T; Sangai T; Sakakibara M; Fujimoto H; Ishigami E; Masuda T; Nakagawa A; Teranaka R; Ota S; Itoga S; Yamamoto N; Nagashima T; Otsuka M
BMC Cancer; 2023 Apr; 23(1):384. PubMed ID: 37106324
[TBL] [Abstract] [Full Text] [Related]
19. Predictive value and dynamic risk stratification of high sensitive basal or stimulated thyroglobulin assay in a long-term thyroid carcinoma cohort.
Fernández-Velasco P; Díaz-Soto G; Pérez López P; Torres Torres B; de Luis D
Endocrine; 2023 Jul; 81(1):116-122. PubMed ID: 36820996
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic value of 12-month response to therapy in pediatric patients with differentiated thyroid cancer.
Zampella E; Piscopo L; Manganelli M; Volpe F; Nappi C; Gaudieri V; Pace L; Schlumberger M; Cuocolo A; Klain M
Endocrine; 2023 Jun; 80(3):612-618. PubMed ID: 36692657
[TBL] [Abstract] [Full Text] [Related]
[Next]
